Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 2
2007 1
2008 1
2009 5
2010 4
2011 10
2012 7
2013 5
2014 11
2015 10
2016 14
2017 10
2018 14
2019 11
2020 14
2021 15
2022 17
2023 11
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
[Groundbreaking basic research].
Helland Å. Helland Å. Tidsskr Nor Laegeforen. 2018 Dec 10;138(20). doi: 10.4045/tidsskr.18.0802. Print 2018 Dec 11. Tidsskr Nor Laegeforen. 2018. PMID: 30539600 Free article. Norwegian. No abstract available.
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: helland a. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. Lancet Oncol. 2017. PMID: 28919011 Clinical Trial.
Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A. Stankovic B, et al. Among authors: helland a. Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018. Front Immunol. 2019. PMID: 30774636 Free PMC article.
Hever kvaliteten på behandling av kreft.
Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K. Helland Å, et al. Tidsskr Nor Laegeforen. 2024 Jan 18;144(1). doi: 10.4045/tidsskr.23.0740. Print 2024 Jan 23. Tidsskr Nor Laegeforen. 2024. PMID: 38258713 Free article. Norwegian. No abstract available.
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.
Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ, Branca RM, Planck M, Staaf J, Orre LM. Lehtiö J, et al. Among authors: helland a. Nat Cancer. 2021 Nov;2(11):1224-1242. doi: 10.1038/s43018-021-00259-9. Epub 2021 Nov 22. Nat Cancer. 2021. PMID: 34870237 Free PMC article.
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Among authors: helland a. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Helland Å, et al. J Transl Med. 2022 May 14;20(1):225. doi: 10.1186/s12967-022-03432-5. J Transl Med. 2022. PMID: 35568909 Free PMC article. Clinical Trial.
[Immunotherapy for malignant pleural mesothelioma].
Farooqi SJ, Bjaanæs MM, Helland Å, Haakensen VD. Farooqi SJ, et al. Among authors: helland a. Tidsskr Nor Laegeforen. 2021 Sep 6;141. doi: 10.4045/tidsskr.21.0503. Print 2021 Sep 7. Tidsskr Nor Laegeforen. 2021. PMID: 34505475 Free article. Norwegian. No abstract available.
[Lung cancer in smokers and never-smokers].
Helland A, Brustugun OT. Helland A, et al. Tidsskr Nor Laegeforen. 2009 Sep 24;129(18):1859-62. doi: 10.4045/tidsskr.08.0652. Tidsskr Nor Laegeforen. 2009. PMID: 19844277 Free article. Review. Norwegian.
Concordance between clinical and pathology TNM-staging in lung cancer.
Solberg S, Nilssen Y, Terje Brustugun O, Magnus Haram P, Helland Å, Møller B, Strand TE, Gyrid Freim Wahl S, Fjellbirkeland L. Solberg S, et al. Among authors: helland a. Lung Cancer. 2022 Sep;171:65-69. doi: 10.1016/j.lungcan.2022.07.014. Epub 2022 Jul 25. Lung Cancer. 2022. PMID: 35926242 Free article.
163 results